Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Rhinology|July 13, 2021
Elective neck irradiation in the management of esthesioneuroblastoma: a systematic review and meta-analysisA De Virgilio, A Costantino, D Sebastiani, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|February 18, 2009
Laparoscopic debulking of bulky lymph nodes in women with cervical cancer: indication and surgical outcomesR Tozzi, F Lavra, T Cassese, et al.
Radiation Oncology (London, England)|November 1, 2019
RapidPlan knowledge based planning: iterative learning process and model ability to steer planning strategiesA Fogliata, L Cozzi, G Reggiori, et al.
Journal of Cancer Research and Clinical Oncology|March 9, 2017
Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancerC Franzese, A Fogliata, G R D'Agostino, et al.
Cancer Treatment Reviews|August 28, 2016
Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?D Franceschini, C Franzese, P Navarria, et al.
Physics in Medicine and Biology|November 14, 1998
Design and characterization of a dynamic multileaf collimatorG Loi, E Pignoli, M Scorsetti, et al.
Anticancer Research|November 2, 2007
Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancerM Scorsetti, P Navarria, A Facoetti, et al.
Critical Reviews in Oncology/Hematology|February 17, 2020
The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the artD Franceschini, F De Rose, S Cozzi, et al.
Neurosurgical Review|May 8, 2007
Intramedullary astrocytoma with granular cell differentiationR Rodriguez y Baena, A Di Ieva, P Colombo, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|October 12, 2012
Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicityF Alongi, A Fogliata, P Navarria, et al.
Pageof 5